PET imaging with F-18 fluorodeoxyglucose for primary lymphoma of bone.
Park
Yeon Hee
YH
Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea. yhpark@kcch.re.kr
Choi
Seong-Jun
SJ
Ryoo
Baek-Yeol
BY
Kim
Heung Tae
HT
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000517:prevention & control*; D049268:Positron-Emission Tomography / Q000379:methods; D011241:Prednisone / Q000008:administration & dosage*; D011379:Prognosis; D019275:Radiopharmaceuticals; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone